In our study, the NLR was suggested to be a factor associated with the prognosis of extensive-stage SCLC patients receiving anti-PD-L1 ICIs combined with chemotherapy, but it may not be a biomarker of the treatment response to such therapy. This evidence concerns the gene CD274 and small cell lung carcinoma.